PMID- 38223486
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240116
IS  - 2035-3006 (Print)
IS  - 2035-3006 (Electronic)
IS  - 2035-3006 (Linking)
VI  - 16
IP  - 1
DP  - 2024
TI  - Plasmablastic Lymphoma. A State-of-the-Art Review: Part 1-Epidemiology, 
      Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, 
      Prognostic Factors, and Special Populations.
PG  - e2024007
LID - 10.4084/MJHID.2024.007 [doi]
LID - e2024007
AB  - This two-part review aims to present a current and comprehensive understanding of 
      the diagnosis and management of plasmablastic lymphoma. The first section, as 
      presented in this paper, reviews epidemiology, etiology, clinicopathological 
      characteristics, differential diagnosis, prognostic variables, and the impact of 
      plasmablastic lymphoma on specific populations. Plasmablastic lymphoma (PBL) is a 
      rare and aggressive form of lymphoma. Previous and modern studies have 
      demonstrated a significant association between the human immunodeficiency virus 
      (HIV) and the development of the disease. The limited occurrence of PBL 
      contributes to a need for a more comprehensive understanding of the molecular 
      mechanisms involved in its etiology. Consequently, the diagnostic procedure for 
      PBL poses a significant difficulty. Among the group of CD20-negative large B-cell 
      lymphomas, PBL can be correctly diagnosed by identifying its exact clinical 
      characteristics, anatomical location, and morphological characteristics. PBL 
      cells do not express CD20 or PAX5 but possess plasmacytic differentiation markers 
      such as CD38, CD138, MUM1/IRF4, Blimp1, and XBP1. PBL must be distinguished from 
      other B-cell malignancies that lack the CD20 marker, including primary effusion 
      lymphoma, anaplastic lymphoma kinase-positive large B-cell lymphoma, and large 
      B-cell lymphoma (LBCL). This condition is frequently associated with infections 
      caused by the Epstein-Barr virus and genetic alterations involving the MYC gene. 
      Despite advances in our comprehension of this disease, the prognosis remains 
      dismal, resulting in a low overall survival rate, although recent reports suggest 
      an apparent tendency towards substantial improvement.
FAU - Bibas, Michele
AU  - Bibas M
AD  - Department of Clinical Research, Hematology. National Institute for Infectious 
      Diseases "Lazzaro Spallanzani" I.R.C.S.S. Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240101
PL  - Italy
TA  - Mediterr J Hematol Infect Dis
JT  - Mediterranean journal of hematology and infectious diseases
JID - 101530512
PMC - PMC10786126
OTO - NOTNLM
OT  - Aggressive Lymphoma
OT  - CD138+
OT  - CD20-negative large B-cell Lymphoma
OT  - CD38+
OT  - HIV
OT  - Oral cavity lymphoma
OT  - People living with HIV
OT  - Plasmablastic Lymphoma
COIS- Competing interests: The authors declare no conflict of Interest.
EDAT- 2024/01/15 06:42
MHDA- 2024/01/15 06:43
PMCR- 2024/01/01
CRDT- 2024/01/15 04:48
PHST- 2023/10/09 00:00 [received]
PHST- 2023/12/12 00:00 [accepted]
PHST- 2024/01/15 06:43 [medline]
PHST- 2024/01/15 06:42 [pubmed]
PHST- 2024/01/15 04:48 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - mjhid-16-1-e2024007 [pii]
AID - 10.4084/MJHID.2024.007 [doi]
PST - epublish
SO  - Mediterr J Hematol Infect Dis. 2024 Jan 1;16(1):e2024007. doi: 
      10.4084/MJHID.2024.007. eCollection 2024.